Biological markers and cardiac remodelling following the myocardial infarction

Olga Gruzdeva, Yulia Dyleva, Evgenya Uchasova, Olga Akbasheva, Victoria Karetnikova, Vasiliy Kashtalap, Aleksandr Shilov, Olga Polikutina, Yulia Slepynina, Olga Barbarash, Olga Gruzdeva, Yulia Dyleva, Evgenya Uchasova, Olga Akbasheva, Victoria Karetnikova, Vasiliy Kashtalap, Aleksandr Shilov, Olga Polikutina, Yulia Slepynina, Olga Barbarash

Abstract

Aim: To assess growth stimulating factor ST2 and N-terminal pro b-type natriuretic peptide (NT-proBNP) levels in the sera of myocardial infraction (MI) patients, and their correlation with the adaptive and maladaptive variants of cardiac remodelling.

Methods: 87 patients (65 male, 22 females; 67±8.36 years) with ST-elevated MI were included in this study, and 67 patients had an adaptive, physiological, while 20 patients had a maladaptive, pathological variant of myocardium remodelling.

Results: On day 1, ST2 and NT-proBNP levels were shown to increase 2.4 and 4.5 folds, respectively, compared with those in the control. ST2 levels in patients with maladaptive remodelling were 1.5-fold higher than those in the adaptive remodelling group. On day 12, a decrease in ST2 levels was observed in both groups. NT-proBNP levels increased 1.8 folds in both groups on day 1, compared with those in the controls. Increased ST2 levels on day 1 after MI were shown to increase the risk of maladaptive remodelling 4.5 folds, while high NT-proBNP levels increased this risk 2.3 times.

Conclusions: ST2 level determination allows us to predict the risk of maladaptive remodelling with a higher sensitivity and specificity than using NT-proBNP levels.

Keywords: NT-proBNP; growth stimulating factor ST2; myocardial infraction; postinfarction remodelling.

Conflict of interest statement

CONFLICTS OF INTEREST: This manuscript has been read and approved by all the authors. This paper is unique and is not under consideration by any other journal and has not been published elsewhere. The authors of this paper report no conflicts of interest. The authors confirm that they have permission to reproduce any copyrighted material.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Figure 4
Figure 4

References

    1. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006; 367:356–67. 10.1016/S0140-6736(06)68074-4
    1. Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol. 1995; 27:849–56. 10.1016/0022-2828(95)90000-4
    1. Gravning J, Smedsrud MK, Omland T, Eek C, Skulstad H, Aaberge L, Bendz B, Kjekshus J, Mørkrid L, Edvardsen T. Sensitive troponin assays and N-terminal pro-B-type natriuretic peptide in acute coronary syndrome: prediction of significant coronary lesions and long-term prognosis. Am Heart J. 2013; 165:716–24. 10.1016/j.ahj.2013.02.008
    1. Barbarash OL, Usoltseva EN. Heart failure treatment under control of natriuretic peptides concentration. Complex Issues of Cardiovascular Diseases. 2014; 1:67–74. in Russian.
    1. Maries L, Manitiu I. Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013; 24:286–89. 10.5830/CVJA-2013-055
    1. Pascual-Figal DA, Januzzi JL. The biology of ST2: the International ST2 Consensus Panel. Am J Cardiol. 2015. (Suppl ); 115:3B–7B. 10.1016/j.amjcard.2015.01.034
    1. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, Iacoviello M, Scicchitano P. A novel cardiac bio-marker: ST2: a review. Molecules. 2013; 18:15314–28. 10.3390/molecules181215314
    1. Barbarash O, Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Akbasheva O, Karetnikova V, Shilov A. Prognostic value of soluble ST2 during hospitalization for ST-segment elevation myocardial infarction. Ann Lab Med. 2016; 36:313–319. 10.3343/alm.2016.36.4.313
    1. Felker GM, Fiuzat M, Thompson V, Shaw LK, Neely ML, Adams KF, Whellan DJ, Donahue MP, Ahmad T, Kitzman DW, Piña IL, Zannad F, Kraus WE, O’Connor CM. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail. 2013; 6:1172–79. 10.1161/CIRCHEARTFAILURE.113.000207
    1. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004; 109:2186–90. 10.1161/01.CIR.0000127958.21003.5A
    1. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358:2148–59. 10.1056/NEJMra0800239
    1. Mathewkutty S, Sethi SS, Aneja A, Shah K, Iyengar RL, Hermann L, Khakimov S, Razzouk L, Esquitin R, Vedanthan R, Benjamin TA, Grace M, Nisenbaum R, et al.. Biomarkers after risk stratification in acute chest pain (from the BRIC Study). Am J Cardiol. 2013; 111:493–98. 10.1016/j.amjcard.2012.10.032
    1. He Q, Wang D, Yang XP, Carretero OA, LaPointe MC. Inducible regulation of human brain natriuretic peptide promoter in transgenic mice. Am J Physiol Heart Circ Physiol. 2001; 280:H368–76. 10.1152/ajpheart.2001.280.1.H368
    1. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Bergmann A, Davies JE, Ng LL. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2008; 51:1857–64. 10.1016/j.jacc.2008.01.041
    1. Khan SQ, Quinn P, Davies JE, Ng LL. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart. 2008; 94:40–43. 10.1136/hrt.2006.108985
    1. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov. 2008; 7:827–40. 10.1038/nrd2660
    1. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008; 117:1936–44. 10.1161/CIRCULATIONAHA.107.728022
    1. Januzzi JL Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res. 2013; 6:493–500. 10.1007/s12265-013-9459-y
    1. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM, McInnes IB, Dargie HJ, McMurray JJ. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010; 55:243–50. 10.1016/j.jacc.2009.08.047
    1. Januzzi JL Jr, Rehman S, Mueller T, van Kimmenade RR, Lloyd-Jones DM. Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients. Clin Chem. 2010; 56:1814–21. 10.1373/clinchem.2010.146506
    1. Januzzi JL Jr, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL, O’Donoghue M, Sakhuja R, Chen AA, van Kimmenade RR, Lewandrowski KB, Lloyd-Jones DM, Wu AH. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007; 50:607–13. 10.1016/j.jacc.2007.05.014
    1. Pascual-Figal DA, Lax A, Perez-Martinez MT, del Carmen Asensio-Lopez M, Sanchez-Mas J, and GREAT Network. Clinical relevance of sST2 in cardiac diseases. Clin Chem Lab Med. 2016; 54:29–35. 10.1515/cclm-2015-0074
    1. Dupuy AM, Curinier C, Kuster N, Huet F, Leclercq F, Davy JM, Cristol JP, Roubille F. Multi-Marker Strategy in Heart Failure: Combination of ST2 and CRP Predicts Poor Outcome. PLoS One. 2016; 11:e0157159. 10.1371/journal.pone.0157159
    1. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106:2961–66. 10.1161/01.CIR.0000038705.69871.D9
    1. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967; 20:457–464. 10.1016/0002-9149(67)90023-9

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다